Prescription EPA and DHA Products
Yes, prescription formulations of EPA and/or DHA are FDA-approved and available in the United States for treating severe hypertriglyceridemia (≥500 mg/dL), with icosapent ethyl being the only omega-3 preparation also approved for cardiovascular risk reduction. 1
Available Prescription Formulations
Three distinct prescription omega-3 fatty acid products are FDA-approved in the United States:
Omega-3 acid ethyl esters (OM3EE) - Contains a mixture of EPA and DHA ethyl esters (marketed as Lovaza®, Omtryg™, and generics) 2, 3
Icosapent ethyl (IPE) - Contains only EPA ethyl esters (marketed as Vascepa®), which is unique as the sole prescription omega-3 approved for both severe hypertriglyceridemia and cardiovascular risk reduction 1, 2
Omega-3 carboxylic acids (OM3CA) - Contains EPA, DHA, and docosapentaenoic acid in free fatty acid form (marketed as Epanova®) 2
FDA-Approved Indications
For severe hypertriglyceridemia (≥500 mg/dL):
- All three prescription formulations are approved as adjunct to diet for reducing triglyceride levels in adults with severe hypertriglyceridemia 1, 2
- The standard dose is 4 grams per day, which reduces triglycerides by 25-30% or more 4, 2, 3
For cardiovascular risk reduction:
- Only icosapent ethyl is FDA-approved as adjunct to maximally tolerated statin therapy to reduce risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated triglycerides (≥150 mg/dL) and established cardiovascular disease or diabetes with multiple risk factors 1
Critical Distinction from Over-the-Counter Products
Prescription omega-3 products are NOT interchangeable with over-the-counter fish oil supplements:
Over-the-counter supplements have variable content and quality, may contain impurities or contaminants, and are not subject to FDA pharmaceutical standards for safety, efficacy, and purity 4, 5, 6
Non-prescription products are not FDA-approved for treating elevated triglycerides and are not recommended for cardiovascular risk reduction 4
The American Heart Association advises that therapy with EPA and DHA to lower very high triglyceride levels should be used only under a physician's care with prescription products 3
Dosing and Administration
The daily dose is 4 grams per day taken as either four 0.5 gram capsules twice daily with food OR two 1 gram capsules twice daily with food 1
Capsules must be swallowed whole and should not be broken, crushed, dissolved, or chewed 1
Patients should engage in appropriate nutritional intake and physical activity before and during treatment 1
Important Safety Considerations
Atrial fibrillation risk:
- The American College of Cardiology notes that increased risk of atrial fibrillation is associated with higher doses (1.8-4 g daily) of prescription omega-3 preparations 4
- In clinical trials, icosapent ethyl was associated with a 50% increased risk of atrial fibrillation or atrial flutter requiring hospitalization (3% vs 2% with placebo), with greater incidence in patients with previous history of atrial arrhythmias 1
Bleeding risk:
- Icosapent ethyl is associated with increased bleeding risk (12% vs 10% with placebo), with serious bleeding events occurring in 3% vs 2% of patients 1
- Risk is greater in patients receiving concomitant antithrombotic medications such as aspirin, clopidogrel, or warfarin 1
Fish allergy:
- Patients with known hypersensitivity to fish and/or shellfish should be informed about potential allergic reactions and advised to discontinue and seek medical attention if reactions occur 1
Effects on Lipid Profile
EPA+DHA formulations reduce triglycerides by ≥30% at 4 g/day but may increase LDL-C by 5-10% in patients with very high triglycerides 2, 7
EPA-only (icosapent ethyl) did not raise LDL-C in patients with very high triglycerides 7
When used for moderate hypertriglyceridemia (150-499 mg/dL), neither EPA+DHA nor EPA-only increase LDL-C when used as monotherapy or combined with statins 7
Both formulations modestly decrease non-HDL cholesterol and apolipoprotein B, indicating reductions in total atherogenic lipoproteins 7
Guideline-Based Treatment Algorithm
For triglycerides 150-499 mg/dL:
- Implement lifestyle modifications and consider statin therapy based on cardiovascular risk 4
- Consider icosapent ethyl if triglycerides remain elevated despite statin therapy, particularly in patients with established cardiovascular disease or diabetes with additional risk factors 4
For triglycerides ≥500 mg/dL:
- Implement aggressive lifestyle modifications with very-low-fat diet (10-15% of calories from fat) 4
- Add prescription omega-3 fatty acids at 4 g/day 4, 7
For triglycerides ≥1,000 mg/dL:
- Implement extreme dietary fat restriction (<5% of calories) until levels decrease to <1,000 mg/dL 4
- Add prescription omega-3 fatty acids and consider fibrate therapy 4
- Address secondary causes aggressively 4
Monitoring Requirements
- Assess lipid levels before initiating therapy and identify other causes of hypertriglyceridemia 1
- Monitor for gastrointestinal disturbances, skin changes, and bleeding when EPA and/or DHA are used for severe hypertriglyceridemia 8
- Periodic monitoring of LDL-C is required as levels may increase by 5-10% with EPA+DHA formulations 2